Atp2a1, a gene associated with increased risk of IBD (48), also showed a significant increase in expression in sulfasalazine-treated ERAP1+/− colitis mice compared to ERAP1+/− controls (p < 0.001) (Figure 7B). Here, ATP2A1 is linked to inflammatory bowel disease.